Phase 3 N=140 MabionCD20 Compared to MabThera in Lymphoma Patients
Diffuse Large B-Cell Lymphoma
Primary: Area Under the Serum Concentration-time Curve From Day 1 to Week 4 (AUC[1-4]) — 1559.51; 1509.79 (μg*day)/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Graft Vs Host Disease · GVHD
Primary: STAT Activity — 9.623 %pSTAT3+CD4+T cells at day +21
Phase 3 N=10 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Head and Neck Squamous Cell Carcinoma · Hypopharyngeal Squamous Cell Carcinoma
Primary: Number of Participants With Dose-limiting Toxicity (DLT) [Lead-in Phase] — 0 Participants
N/A N=42 Standing Balance as the Fifth Vital Sign in Clinical Setting
Accidental Fall · Postural Balance · Clinical Decision-making
Primary: Percentage of Balance-Related Diagnoses — 12118; 11763; 19904 unique visits — p=<0.0001
Phase 3 N=1,537 Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving 20 Percentage (%) Improvement in American College of Rheumatology Criteria (ACR20) at Week 12 Superiority Comparison With Placebo…
N/A N=93 Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV
Hiv · Aids
Primary: Viral Suppression — 25; 25; 19 Participants
N/A N=275 Shrinking the Size of the Tobacco Power Wall
Tobacco Use
Primary: Proportion at Risk for Cigarette Smoking — .18; .39; .26 proportion of participants
N/A N=61 Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
Hypertension
Primary: Change in Fasting Plasma Glucose From Week 4 to Week 16 — -5.6; 2.3 mg/dL
Phase 2 N=24 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Chronic Graft vs Host Disease · Chronic Graft-Versus-Host Disease
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0 Participants
Phase 2 N=13 A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Lung Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) Observed During the Dose Escalation to Determine the Maximum Tolerated Dose (MTD) — 0; 0 Participants
Phase 3 N=43 Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD
Von Willebrand Diseases
Primary: Total Annualized Bleeding Rate (TABR) — 3.73; 4.28; 6.31; 5.24 bleeding events per year
Phase 2 N=121 A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects
Colonoscopy
Primary: % of Subjects With Successful Bowel Preparation — 17; 37; 37; 16 Participants
N/A N=185 Dexcom G6 Intervention Study
Diabetes Mellitus
Primary: Mean Daily Blood Glucose (BG) Concentration While Hospitalized — 186.8; 183.2 mg/dL
N/A N=59 Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation
Mild Cognitive Impairment
Primary: Rey Auditory Verbal Learning Test (Total Delayed Recall) — 6.43; 7.83 score on a scale — p=0.11
N/A N=15 SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
Alzheimer Disease
Primary: Percentage of Skill Pages in SAGE-LEAF Accessed by a Participant — 72 Percentage of skill pages